Welcome to our dedicated page for Editas Medicine SEC filings (Ticker: EDIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CRISPR breakthroughs capture headlines, but deciphering the paperwork behind them is another story. Editas Medicine’s 10-K teems with gene-editing science, licensing deals, and clinical risk factors, while rapid-fire 8-K updates document FDA feedback and strategic alliances. If you have ever typed “Editas Medicine insider trading Form 4 transactions” or searched for the “Editas Medicine quarterly earnings report 10-Q filing,” you know locating the right details can be time-consuming.
Stock Titan solves that problem. Our AI-powered summaries turn dense biotech language into plain English, so “understanding Editas Medicine SEC documents with AI” becomes effortless. Receive “Editas Medicine Form 4 insider transactions real-time” alerts, read an “Editas Medicine annual report 10-K simplified” digest, or skim an “Editas Medicine 8-K material events explained” brief—each delivered moments after EDGAR posts. Interactive dashboards add context, providing cash-burn trends, collaboration revenue snapshots, and side-by-side comparisons that drive sharper decisions. From “Editas Medicine earnings report filing analysis” to the “Editas Medicine proxy statement executive compensation,” every document is linked to its original source and annotated for clarity.
Why focus on filings? Small shifts in trial design, patent disputes, or milestone payments can move Editas shares long before commercial revenue. With our platform you can:
- Track gene-editing pipeline disclosures the instant they appear.
- Monitor “Editas Medicine executive stock transactions Form 4” to gauge management sentiment.
- Compare quarterly R&D spend without combing through footnotes.
Complex biotech paperwork now reads simply. Explore every Editas Medicine SEC filing explained simply—powered by AI, updated in real time, and ready when you are.
Editas Medicine reported Q3 2025 results with collaboration revenue of $7.5 million driven by a BMS milestone. Operating expenses fell sharply after the 2024 program discontinuation, with R&D at $19.8 million and G&A at $12.3 million. The quarter’s operating loss was $24.5 million and net loss was $25.1 million, or $0.28 per share.
Cash and cash equivalents were $165.6 million, and management states existing cash is expected to fund operations into the third quarter of 2027. Year to date, the company recorded $66.9 million of restructuring and impairment charges tied to the wind-down of its ex vivo program, while interest expense reflects its sale of certain future Vertex-related payments. Common shares outstanding were 97,618,660 as of October 31, 2025.
The company raised $25.8 million net through its at-the-market equity program in the first nine months of 2025 and had $123.6 million of capacity remaining as of September 30, 2025. Authorized common stock increased to 390,000,000 shares. Editas is prioritizing in vivo programs, including EDIT-401 for LDL-C reduction.
Editas Medicine reported that it furnished a press release announcing financial results for the fiscal quarter ended September 30, 2025, along with other business highlights.
The press release was provided as Exhibit 99.1 and designated as furnished, not filed. The company’s common stock trades on Nasdaq under the symbol EDIT.
Linda C. Burkly, Executive Vice President and Chief Scientific Officer of Editas Medicine, reported a sale of 710 shares of the issuer's common stock on 09/03/2025 at a price of $2.5961 per share. The filing states the sale was effected under a durable automatic sales instruction plan adopted July 3, 2023, to satisfy tax withholding triggered by restricted stock units that vested on 09/02/2025, and the sale was not a discretionary trade. Following the transaction Burkly beneficially owns 69,490 shares, which includes 5,802 shares acquired under the company Employee Stock Purchase Plan.
Editas Medicine insider sale disclosed on Form 4: Amy Parison, SVP and Chief Financial Officer, reported a transaction dated 09/03/2025 showing the disposition of 458 shares of Editas Medicine common stock at a price of $2.5961 per share. After the sale, Ms. Parison beneficially owned 16,369 shares, held directly. The filing states the sale was effected under a durable automatic sales instruction plan adopted July 7, 2022, to satisfy tax withholding obligations tied to the vesting of restricted stock units on 09/02/2025, and that the sale was not a discretionary trade by the reporting person.
Editas Medicine director and CEO Gilmore O'Neill sold 5,592 shares of Editas Medicine (EDIT) on 09/03/2025 at $2.5961 per share under a pre-existing Rule 10b5-1 automatic sales plan. The filing states the sale was to satisfy tax withholding obligations arising from restricted stock units that vested on 09/02/2025 and was not a discretionary trade. After the transaction the reporting person beneficially owned 274,690 shares.
Editas Medicine (EDIT) Form 144 notice reports a proposed sale of 7,000 shares of Common Stock to be executed through ETrade on 09/03/2025 on Nasdaq with an aggregate market value of $19,110.00. The filing shows these shares were acquired on 09/02/2025 through restricted stock unit vesting (equity compensation), with 11,294 shares listed as acquired on that date. The filing also discloses a sale by Gilmore O'Neill of 15,192 shares on 06/03/2025 for gross proceeds of $26,195.57. The notice includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.
Editas Medicine (EDIT) submitted a Form 144 disclosing a proposed sale of 800 shares of common stock with an aggregate market value of $2,184, listed for sale on Nasdaq and dated approximately 09/03/2025. The securities were acquired on 09/02/2025 through restricted stock unit vesting (1,550 shares acquired) and payment was in the form of equity compensation. The filing also reports two prior sales by the same person in the past three months: 726 shares on 06/03/2025 ($1,251.84) and 5,121 shares on 07/31/2025 ($12,756.92). The form includes the standard attestation that the seller is unaware of undisclosed material adverse information.
Editas Medicine (EDIT) reported a net loss of $129.3 million for the six months ended June 30, 2025, or $1.54 per share, widening its accumulated deficit to $1.6 billion. Total assets fell to $210.6 million from $341.6 million at year-end 2024, and stockholders' equity declined to $19.2 million. Cash and cash equivalents were $138.5 million and marketable securities were $39.9 million, totaling $178.5 million in liquid investments.
The company discontinued its ex vivo reni-cel program and initiated a workforce reduction of approximately 180 positions (about 65%), recording $66.9 million of restructuring and impairment charges in the six months and $79.2 million since the December 2024 decision. Editas received $57.0 million from DRI under a sale-of-future-revenues agreement (accounted for as debt; estimated effective interest rate 15.1%, liability $56.7 million) and has an amended ATM facility with $141.4 million remaining capacity after $8.6 million of sales. Management expects existing cash, cash equivalents and marketable securities to fund operations for at least twelve months from the consolidated financial statement issuance date.
FAQ
What is the current stock price of Editas Medicine (EDIT)?
What is the market cap of Editas Medicine (EDIT)?
